Citeline, Biomedtracker: see the drug development process th...
Catch up on any missed COVID-19 24 hour webinar sessions
If you’re a senior business development and licensing professional in pharma or biotech, it’s your job to ensure that your company’s revenue pipeline is full of viable opportunities and accelerate growth for your organisation. But that’s a huge challenge when you’re busy juggling in and out licensing and partnership opportunities, benchmarking key deals and patents, and trying to assess how the latest healthcare and pharma trends might affect your current and future business strategies.
You need Pharma Intelligence, your one trusted source of pharma information and perspective:
Datamonitor Healthcare: data analysis and insight, Pink Shee...
By Tara Hansen
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.
Datamonitor Healthcare: data analysis and insight
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: